SG Americas Securities
OVID icon

SG Americas Securities’s Ovid Therapeutics OVID Stock Holding History

SG Americas Securities’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-43,028
Closed -$13K – 3418
2025
Q1 		$13K Buy
43,028
+5,392
+14% +$3.32K ﹤0.01% 3401
2024
Q4 		$35K Buy
37,636
+17,172
+84% +$19.2K ﹤0.01% 2967
2024
Q3 		$24K Buy
+20,464
New +$21.4K ﹤0.01% 3335
2024
Q2 		– Sell
-35,938
Closed -$110K – 3190
2024
Q1 		$110K Sell
35,938
-3,854
-10% -$12.9K ﹤0.01% 2484
2023
Q4 		$128K Buy
39,792
+13,728
+53% +$46.9K ﹤0.01% 2550
2023
Q3 		$100K Buy
+26,064
New +$93.7K ﹤0.01% 2794
2020
Q3 		– Sell
-23,422
Closed -$173K – 3249
2020
Q2 		$173K Buy
+23,422
New +$110K ﹤0.01% 2969
2019
Q1 		– Sell
-18,870
Closed -$46K – 3545
2018
Q4 		$46K Buy
+18,870
New +$86.1K ﹤0.01% 2833

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

SG Americas Securities's OVID Position: Q2 2025 in Review

SG Americas Securities sold out of Ovid Therapeutics (OVID) in Q2 2025, closing a stake of 43,028 shares — an estimated $13K sold.

SG Americas Securities first reported a position in OVID in Q4 2018 and held it in 8 quarters. The position peaked at $173K in Q2 2020. 71 funds tracked by Wall St. Rank hold OVID as of Q2 2025.

  • SG Americas Securities reported no remaining Ovid Therapeutics position as of Q2 2025 after selling out during the quarter.
  • SG Americas Securities sold 43,028 Ovid Therapeutics shares in Q2 2025, an estimated $13K.
  • SG Americas Securities first reported a position in Ovid Therapeutics in Q4 2018 and held it in 8 quarters.
  • SG Americas Securities's Ovid Therapeutics position peaked at $173K in Q2 2020.
  • 71 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2025.

Based on SG Americas Securities's 13F filing for Q2 2025, filed 8 Aug 2025.